

#### CERTIFICATE OF MAILING

ertify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date with sufficient postage as first class mail in an envelope addre ner for Patents, Washington, D.C. 20231

HESNA J PFEIFFER

Type or print name

27 FEBRUARY 2003

Date

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1645

BAIR ET AL.

**APPLICATION NO: 10/024,935** FILED: DECEMBER 19, 2001

FOR: INHIBITORS OF THE E2F-1/CYCLIN INTERACTION FOR CANCER THERAPY

RECEIVED

MAR 0 5 2003

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, D.C. 20231

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references were cited in a search report in a corresponding International application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080 (862) 778-7903

Date: February 27, 2003

Hesna J. Pfeiffer Attorney for Applicants

Reg. No. 22,640

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use severy Fiber if nocessary)

MAR 0 3 7003

ATTY. DOCKET NO. 4-31664A/USN APPLICATION NO. 10/024,935 APPLICANT BAIR ET AL. FILING DATE DECEMBER 19, 2001

Group 1645

### **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
A	AA						
A	ΑВ						
A	4C					_	NEL 5 2003
A	AD					DECE	14-
А	Æ					710	5 2003
Д	٦F					MAR	20100
Д	4G					١٩٢١	TER 1000100
Д	АН					TECH UE	
Д	AI						
Д	٦J						
Д	λK						
Δ	AL.						

### **FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
АМ	WO 01/40142	6/7/01	PCT			⊡	
AN	EP 0666270	8/9/95	EPO			⊡	
AO							
AP							
AQ							

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	A. Brinker, Eur. Biochem. <u>267</u> , 5085-5092 (2000) XP-002212270
 AS	MA. Ikeda et al., Molecular and Cellular Biology, <u>13</u> , 11, 7029-7035 (Nov. 1993)
 AT	PCT Search report, appln PCT/EP 01/15006, dates 18/09/2002

EXAMINER

DATE CONSIDERED

<sup>\*</sup>EXAMINER Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.